Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income towards Parent Company (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Income towards Parent Company for 8 consecutive years, with -$84.2 million as the latest value for Q1 2026.

  • For Q1 2026, Income towards Parent Company fell 13.04% year-over-year to -$84.2 million; the TTM value through Mar 2026 reached -$359.5 million, down 29.09%, while the annual FY2025 figure was -$349.8 million, 33.56% down from the prior year.
  • Income towards Parent Company hit -$84.2 million in Q1 2026 for Kymera Therapeutics, up from -$98.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$19.4 million in Q4 2023 and bottomed at -$98.0 million in Q4 2025.
  • Average Income towards Parent Company over 5 years is -$60.2 million, with a median of -$57.6 million recorded in 2023.
  • Year-over-year, Income towards Parent Company skyrocketed 49.95% in 2023 and then crashed 317.34% in 2024.
  • Kymera Therapeutics' Income towards Parent Company stood at -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then plummeted by 317.34% to -$80.8 million in 2024, then decreased by 21.25% to -$98.0 million in 2025, then grew by 14.05% to -$84.2 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$84.2 million, -$98.0 million, and -$92.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.